BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA), announced today that it has shipped a pre-commercial version of its novel Plexera™ KX5 Analyzer. Plexera’s first Early Access Partner is a pharmaceutical company who will be evaluating the system as a tool for screening and characterizing antibody libraries. As part of the early access agreement, the customer will have a 90 day period following installation to evaluate the platform. Pending positive evaluation results, the customer has agreed to purchase a commercial version of the KX5 Analyzer. A second early access partner is anticipated in the second quarter.
